 Connection
Kurt Stenmark to PPAR gamma
This is a "connection" page, showing publications Kurt Stenmark has written about PPAR gamma.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.748 |
|
|
|
-
Stenmark KR, Tuder RM. Peroxisome Proliferator-activated Receptor ? and Mitochondria: Drivers or Passengers on the Road to Pulmonary Hypertension? Am J Respir Cell Mol Biol. 2018 05; 58(5):555-557.
Score: 0.529
-
Rashid J, Alobaida A, Al-Hilal TA, Hammouda S, McMurtry IF, Nozik-Grayck E, Stenmark KR, Ahsan F. Repurposing rosiglitazone, a PPAR-? agonist and oral antidiabetic, as an inhaled formulation, for the treatment of PAH. J Control Release. 2018 06 28; 280:113-123.
Score: 0.132
-
Takeda K, Okamoto M, de Langhe S, Dill E, Armstrong M, Reisdorf N, Irwin D, Koster M, Wilder J, Stenmark KR, West J, Klemm D, Gelfand EW, Nozik-Grayck E, Majka SM. Peroxisome proliferator-activated receptor-g agonist treatment increases septation and angiogenesis and decreases airway hyperresponsiveness in a model of experimental neonatal chronic lung disease. Anat Rec (Hoboken). 2009 Jul; 292(7):1045-61.
Score: 0.072
-
Crossno JT, Garat CV, Reusch JE, Morris KG, Dempsey EC, McMurtry IF, Stenmark KR, Klemm DJ. Rosiglitazone attenuates hypoxia-induced pulmonary arterial remodeling. Am J Physiol Lung Cell Mol Physiol. 2007 Apr; 292(4):L885-97.
Score: 0.015
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|